6 results on '"Raje, Noopur"'
Search Results
2. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins.
- Author
-
Panaroni C, Fulzele K, Mori T, Siu KT, Onyewadume C, Maebius A, and Raje N
- Subjects
- Adipocytes cytology, Adipocytes pathology, Animals, Cell Line, Coculture Techniques, Humans, Male, Mice, SCID, Multiple Myeloma pathology, Tumor Cells, Cultured, Mice, Adipocytes metabolism, Fatty Acid Transport Proteins metabolism, Fatty Acids metabolism, Lipolysis, Multiple Myeloma metabolism
- Abstract
Adipocytes occupy 70% of the cellular volume within the bone marrow (BM) wherein multiple myeloma (MM) originates and resides. However, the nature of the interaction between MM cells and adipocytes remains unclear. Cancer-associated adipocytes support tumor cells through various mechanisms, including metabolic reprogramming of cancer cells. We hypothesized that metabolic interactions mediate the dependence of MM cells on BM adipocytes. Here we show that BM aspirates from precursor states of MM, including monoclonal gammopathy of undetermined significance and smoldering MM, exhibit significant upregulation of adipogenic commitment compared with healthy donors. In vitro coculture assays revealed an adipocyte-induced increase in MM cell proliferation in monoclonal gammopathy of undetermined significance/smoldering MM compared with newly diagnosed MM. Using murine MM cell/BM adipocyte coculture assays, we describe MM-induced lipolysis in adipocytes via activation of the lipolysis pathway. Upregulation of fatty acid transporters 1 and 4 on MM cells mediated the uptake of secreted free fatty acids (FFAs) by adjacent MM cells. The effect of FFAs on MM cells was dose dependent and revealed increased proliferation at lower concentrations vs induction of lipotoxicity at higher concentrations. Lipotoxicity occurred via the ferroptosis pathway. Exogenous treatment with arachidonic acid, a very-long-chain FFA, in a murine plasmacytoma model displayed a reduction in tumor burden. Taken together, our data reveal a novel pathway involving MM cell-induced lipolysis in BM adipocytes and suggest prevention of FFA uptake by MM cells as a potential target for myeloma therapeutics., (© 2022 by The American Society of Hematology.)
- Published
- 2022
- Full Text
- View/download PDF
3. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
- Author
-
Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, and Jakubowiak AJ
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Autografts, Dexamethasone administration & dosage, Dexamethasone adverse effects, Disease-Free Survival, Female, Humans, Lenalidomide administration & dosage, Lenalidomide adverse effects, Male, Middle Aged, Oligopeptides administration & dosage, Oligopeptides adverse effects, Progression-Free Survival, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Hematopoietic Stem Cell Transplantation, Multiple Myeloma diagnosis, Multiple Myeloma mortality, Multiple Myeloma therapy
- Abstract
In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd induction, ASCT, 4 cycles of KRd consolidation, and 10 cycles of KRd maintenance. The primary end point was rate of stringent complete response (sCR) after 8 cycles of KRd with a predefined threshold of ≥50% to support further study. Seventy-six patients were enrolled with a median age of 59 years (range, 40-76 years), and 35.5% had high-risk cytogenetics. The primary end point was met, with an sCR rate of 60% after 8 cycles. Depth of response improved over time. On intent-to-treat (ITT), the sCR rate reached 76%. The rate of minimal residual disease (MRD) negativity using modified ITT was 70% according to next-generation sequencing (<10-5 sensitivity). After median follow-up of 56 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 72% and 84% for ITT, 85% and 91% for MRD-negative patients, and 57% and 72% for patients with high-risk cytogenetics. For high-risk patients who were MRD negative, 5-year rates were 77% and 81%. Grade 3 to 4 adverse events included neutropenia (34%), lymphopenia (32%), infection (22%), and cardiac events (3%). There was no grade 3 to 4 peripheral neuropathy. Patients with NDMM treated with KRd with ASCT achieved high rates of sCR and MRD-negative disease at the end of KRd consolidation. Extended KRd maintenance after consolidation contributed to deepening of responses and likely to prolonged PFS and OS. Safety and tolerability were manageable. This trial was registered at www.clinicaltrials.gov as #NCT01816971., (© 2020 by The American Society of Hematology.)
- Published
- 2020
- Full Text
- View/download PDF
4. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
- Author
-
Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, and Anderson K
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Dexamethasone administration & dosage, Dexamethasone adverse effects, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma mortality, Neoplasm Recurrence, Local drug therapy, Progression-Free Survival, Thalidomide administration & dosage, Thalidomide adverse effects, Thalidomide analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma drug therapy
- Abstract
This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Patients who had received ≥2 prior MM therapies, including lenalidomide and a proteasome inhibitor (PI), were enrolled and received isatuximab at 5, 10, or 20 mg/kg (weekly for 4 weeks, followed by every 2 weeks), pomalidomide 4 mg (days 1-21), and dexamethasone 40 mg (weekly) in 28-day cycles until progression/intolerable toxicity. The primary objective was to determine the safety and recommended dose of isatuximab with this combination. Secondary objectives included evaluation of pharmacokinetics, immunogenicity, and efficacy. Forty-five patients received isatuximab (5 [n = 8], 10 [n = 31], or 20 [n = 6] mg/kg). Patients received a median of 3 (range, 1-10) prior lines; most were refractory to their last regimen (91%), with 82% lenalidomide-refractory and 84% PI-refractory. Median treatment duration was 9.6 months; 19 patients (42%) remain on treatment. Most common adverse events included fatigue (62%), and upper respiratory tract infection (42%), infusion reactions (42%), and dyspnea (40%). The most common grade ≥3 treatment-emergent adverse event was pneumonia, which occurred in 8 patients (17.8%). Hematologic laboratory abnormalities were common (lymphopenia, leukopenia, anemia, 98% each; neutropenia, 93%; and thrombocytopenia, 84%). Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months. These results demonstrate potential meaningful clinical activity and a manageable safety profile of isatuximab plus pomalidomide/dexamethasone in heavily pretreated patients with RRMM. The 10 mg/kg weekly/every 2 weeks isatuximab dose was selected for future studies. This trial was registered at www.clinicaltrials.gov as #NCT02283775., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
5. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
- Author
-
Lendvai N, Yee AJ, Tsakos I, Alexander A, Devlin SM, Hassoun H, Korde N, Lesokhin AM, Landau H, Mailankody S, Koehne G, Chung DJ, Landgren O, Raje NS, and Giralt S
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Anilides therapeutic use, Multiple Myeloma drug therapy, Neoplasm Recurrence, Local drug therapy, Protein Kinase Inhibitors therapeutic use, Pyridines therapeutic use, Receptor Protein-Tyrosine Kinases antagonists & inhibitors
- Published
- 2016
- Full Text
- View/download PDF
6. To the editor: Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.
- Author
-
Lendvai, Nikoletta, Yee, Andrew J., Tsakos, Ioanna, Alexander, Aeri, Devlin, Sean M., Hassoun, Hani, Korde, Neha, Lesokhin, Alexander M., Landau, Heather, Mailankody, Sham, Koehne, Guenther, Chung, David J., Landgren, Ola, Raje, Noopur S., and Giralt, Sergio
- Subjects
- *
PROTEIN-tyrosine kinases , *MULTIPLE myeloma - Abstract
A letter to the editor is presented in response to the article "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth" by F. M. Yakes, and colleagues in the 2011 issue.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.